tradingkey.logo
tradingkey.logo
Pesquisar

Pacific Biosciences of California Inc

PACB
Adicionar à lista de desejos
1.120USD
-0.090-7.44%
Fechamento 05/15, 16:00ETCotações atrasadas em 15 min
347.87MValor de mercado
PerdaP/L TTM

Pacific Biosciences of California Inc

1.120
-0.090-7.44%

Mais detalhes de Pacific Biosciences of California Inc Empresa

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Informações de Pacific Biosciences of California Inc

Código da empresaPACB
Nome da EmpresaPacific Biosciences of California Inc
Data de listagemOct 27, 2010
CEOHenry (Christian O)
Número de funcionários575
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 27
Endereço1305 O'brien Drive
CidadeMENLO PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94025
Telefone16505218000
Sitehttps://www.pacb.com/
Código da empresaPACB
Data de listagemOct 27, 2010
CEOHenry (Christian O)

Executivos da empresa Pacific Biosciences of California Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.25M
+9.33%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
132.82K
+17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
132.82K
+17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
22.82K
--
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.25M
+9.33%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
132.82K
+17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
132.82K
+17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
22.82K
--
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Consumable revenue
81.94M
51.21%
Instrument revenue
53.82M
33.64%
Service And Other
24.25M
15.15%
Por RegiãoUSD
Nome
Receita
Proporção
North America
72.80M
45.50%
Europe (including the Middle East and Africa)
44.05M
27.53%
Asia Pacific
43.16M
26.97%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumable revenue
81.94M
51.21%
Instrument revenue
53.82M
33.64%
Service And Other
24.25M
15.15%

Distribuição de ações

Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
Outro
68.81%
Investidores
Investidores
Proporção
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
Outro
68.81%
Tipos de investidores
Investidores
Proporção
Investment Advisor
34.22%
Investment Advisor/Hedge Fund
10.46%
Hedge Fund
8.97%
Holding Company
6.58%
Research Firm
2.49%
Individual Investor
1.15%
Corporation
1.13%
Venture Capital
0.20%
Bank and Trust
0.17%
Outro
34.63%

Participação acionária institucional

Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
540
192.85M
62.12%
-19.48M
2025Q4
549
169.06M
56.00%
-65.22M
2025Q3
566
166.98M
55.32%
-97.69M
2025Q2
600
214.62M
71.52%
-110.62M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
ARK Investment Management LLC
37.26M
12.34%
+6.34M
+20.50%
Dec 31, 2025
SoftBank Group Corp
20.45M
6.77%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
20.30M
6.72%
+431.05K
+2.17%
Dec 31, 2025
Geode Capital Management, L.L.C.
7.08M
2.34%
+172.09K
+2.49%
Dec 31, 2025
Amova Asset Management Co., Ltd.
7.81M
2.59%
-868.98K
-10.01%
Dec 31, 2025
State Street Investment Management (US)
5.91M
1.96%
+2.58K
+0.04%
Dec 31, 2025
D. E. Shaw & Co., L.P.
4.44M
1.47%
+4.44M
--
Dec 31, 2025
Millennium Management LLC
4.34M
1.44%
-572.23K
-11.64%
Dec 31, 2025
Point72 (DIFC) Ltd
4.27M
1.41%
+1.81M
+73.65%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
ARK Genomic Revolution ETF
2.3%
iShares Genomics Immunology and Healthcare ETF
1.31%
Invesco NASDAQ Future Gen 200 ETF
0.96%
Global X Genomics & Biotechnology ETF
0.69%
ARK Innovation ETF
0.58%
AXS Green Alpha ETF
0.58%
WisdomTree BioRevolution Fund
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
Ver Mais
ARK Genomic Revolution ETF
Proporção2.3%
iShares Genomics Immunology and Healthcare ETF
Proporção1.31%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.96%
Global X Genomics & Biotechnology ETF
Proporção0.69%
ARK Innovation ETF
Proporção0.58%
AXS Green Alpha ETF
Proporção0.58%
WisdomTree BioRevolution Fund
Proporção0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.09%
ProShares Ultra Nasdaq Biotechnology
Proporção0.08%
Invesco Nasdaq Biotechnology ETF
Proporção0.07%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI